PURPOSE: We performed a comprehensive survey of annexin I, II and VII protein expression in patient matched benign prostatic epithelium (BPE), androgen stimulated prostate cancer (AS-CaP) and recurrent prostate cancer (R-CaP). MATERIALS AND METHODS: Annexin I, II and VII was immunostained in 23 matched pairs of BPE and AS-CaP specimens, and in 25 R-CaP specimens. Protein expression was assessed visually and using color digital video image analysis. RESULTS: The expression levels of annexins I and II was decreased from BPE to AS-CaP in all patients examined using visual assessment (22 of 22) or digital image analysis (18 of 18 for annexin I and 22 of 22 for annexin II). Annexin I mean optical density (MOD) decreased by 69% (0.718 to 0.222, p <0.0001) and annexin II MOD decreased by 71% (0.820 to 0.238, p <0.0001). Annexin I MOD further decreased almost 50% in R-CaP compared with AS-CaP (0.117 vs 0.222, p <0.0065) and annexin II MOD further declined by 37% (AS-CaP 0.238 vs R-CaP 0.150, p <0.0001). Annexin VII MOD showed no significant change between BPE and AS-CaP (0.229 and 0.214, respectively) but it decreased 14% in R-CaP vs AS-CaP (0.184 vs 0.214, p <0.0051). CONCLUSIONS: Annexins I and II expression are decreased in AS-CaP compared with BPE and a further reduction is observed with progression from AS-CaP to R-CaP. Annexin VII protein expression is decreased in R-CaP, although AS-CaP and BPE are similar. This study suggests that the dysregulations of annexin proteins I, II and VII are important events in prostate carcinogenesis and progression.
No takes yet. Share an insight, caveat, or question.
Smitherman et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: